Research Labs Review: 'Not for Human Use' Is on Every Product Page, and It Means It

This designation is widely misunderstood, deliberately in some quarters, so here it is plainly. RUO is a real regulatory category. Reagents supplied for laboratory investigation — cell culture, assay development, analytical work — are lawfully sold without drug approval because they are not intended for administration to people or animals. Genuine research institutions buy RUO materials constantly and there is nothing improper about the category existing. What RUO material has not been through: No FDA review of safety or effectiveness for any human use. No sterility requirement. This is the one that matters most and is covered in detail below. No pharmaceutical-grade manufacturing requirement. "GMP-aligned" and "our partner labs follow GMP protocols" are the site's own phrasing. GMP-aligned is not the same as an FDA-registered facility operating under CGMP and subject to inspection, and the distinction is not cosmetic. No clinical oversight. No prescriber, no screening for contraindications, no dose titration, no monitoring, no one to call when something goes wrong. No pharmacovigilance. Adverse events are not collected, so nobody — including the vendor — knows what is happening to people using these. Why the naming convention matters. The site lists "GLP-1 (SG)", "GLP-2 (TZ)" and "GLP-3 (RT)". Those initials correspond to well-known GLP-1 receptor agonist molecules, and the products are merchandised under a "GLP / Metabolic Research" category. A storefront with same-day consumer shipping, a toll-free support line and a two-hour response promise is not built for institutional procurement, which runs on purchase orders and account managers. One item deserves particular attention. The catalogue's third GLP entry corresponds to a triple-agonist molecule that remains investigational and is not approved by any regulator anywhere in the world. Its clinical trial programme is ongoing. There is no established human dose, no approved indication, no completed safety profile, and no antidote if something goes wrong. Buying and self-administering an unapproved investigational compound outside a trial means accepting risks that the trials themselves have not yet finished characterising.

If you read one section, read this one. The purity number on the certificate does not tell you what you need to know. Purity and sterility are entirely different measurements. HPLC purity at 99% tells you the proportion of the material that is the intended peptide rather than related substances. It says nothing about whether the vial contains bacteria, fungi or bacterial endotoxin. A vial can be 99% pure and microbiologically contaminated at the same time, and one test will never detect the other. What sterile pharmaceutical manufacturing involves that RUO production does not require: aseptic processing under validated conditions, terminal sterilisation or sterile filtration, environmental monitoring, sterility testing to USP standards, and bacterial endotoxin testing. Endotoxin is the point people miss — it is a bacterial cell wall fragment that survives sterilisation, is not alive, and causes fever, shock and inflammatory reactions when injected. A vial can be sterile and still contain enough endotoxin to make you seriously ill. What injecting a non-sterile preparation can cause: injection site abscess, cellulitis, sepsis, endocarditis — an infection of the heart valves that carries substantial mortality and often requires surgery. These are not theoretical; they are the documented consequences of non-sterile injection in every context where it occurs. Then there is reconstitution. RUO peptides ship as lyophilised powder and must be reconstituted, usually with bacteriostatic water, before use. This introduces two further problems: Sterile technique. Every step — vial stopper disinfection, needle handling, storage after reconstitution — is a point at which contamination enters. This is a trained skill, not an intuition. Dosing arithmetic. Converting milligrams of powder plus millilitres of diluent into units on an insulin syringe is where serious overdoses happen. A decimal error in that calculation is a tenfold dose. With a GLP-1 that means severe protracted vomiting and dehydration; with a growth hormone secretagogue or an unapproved triple agonist, the consequences are less predictable and less reversible. And if you do become unwell, the clinician treating you will be working without knowing what you took, at what dose, or what was in it. That is a materially worse position than any prescribed alternative.

Taking the catalogue on its own terms, here is where the human evidence stands. In every case, the evidence question is separate from the sterility and oversight problems above — a compound with good evidence delivered in an unregulated vial is still an unregulated vial. GLP-1 receptor agonists (semaglutide, tirzepatide analogues). The underlying molecules have excellent evidence — large randomised trials, FDA approval, well-characterised dosing and safety. That evidence belongs to the approved products made under pharmaceutical manufacturing controls. It does not transfer to a research-grade vial, and the dose titration schedules that make these drugs tolerable were designed around a prescriber managing them. The investigational triple agonist. In trials. Not approved anywhere. No established human dose. Nothing more can honestly be said. BPC-157. A synthetic peptide marketed for tendon, ligament and gut healing. Essentially all the evidence is in rodents. There are no adequate published human trials for the indications it is sold for. FDA has placed BPC-157 in a category of substances it considers to present significant safety risks for compounding, and WADA prohibits it in sport. Whatever it may eventually turn out to do, it currently has an animal evidence base and a regulatory position against it. TB-500 (thymosin beta-4 fragment). Similar picture — preclinical interest, no human efficacy trials, prohibited in sport. Ipamorelin. A growth hormone secretagogue. It does raise growth hormone — that is real pharmacology. What is not established is benefit in healthy adults, and growth hormone excess carries genuine risks: insulin resistance, fluid retention, joint pain, carpal tunnel syndrome, and theoretical concerns about promoting growth of existing malignancies. Adult growth hormone deficiency is a diagnosis made by endocrine stimulation testing, not by a website. NAD+. No controlled human evidence that injected NAD+ improves energy, cognition or ageing outcomes. Interesting biology; not a demonstrated clinical benefit. GHK-Cu. A copper peptide with reasonable evidence topically in skincare. Injecting it is a different proposition with a different, absent, evidence base. A note for anyone who competes. Several of these are on the WADA Prohibited List, and "I bought it as a research chemical" is not a defence in an anti-doping proceeding. Strict liability applies.

It would be dishonest to write only the risks, so here is what is genuinely better than the worst of this category. It states the RUO status plainly on product pages. "For Research Use Only (RUO). Not for human or veterinary use." Many vendors in this space bury that or omit it. Stating it clearly is the correct behaviour and it is the single most important thing a reader should take from the site. It publishes analytical detail. Molecular formula, molecular weight, reference numbers, HPLC data and COA links on product pages — described as "full catalog with COA links, HPLC data, and transparent pricing on every product page. No gatekeeping." Publishing certificates rather than claiming testing is meaningfully better practice. It publishes a phone number — (888) 898-1893 — and states an average support response under two hours. It states US manufacturing and GMP-aligned partner labs. Same-day shipping on orders before noon Pacific. How to read a COA if you are evaluating any peptide vendor: Check it is batch-matched to the lot number on the vial you receive, not a generic sample document. Check the issuing laboratory is independent of the seller and identifiable. Check what was tested. HPLC purity alone is not enough. Ask specifically whether sterility and bacterial endotoxin were tested, because for anything injectable those are the tests that matter and they are usually absent. Check the date. The honest conclusion on the vendor: within its stated category, this is a comparatively transparent operation. The problem is not that it is a bad research-chemical vendor. The problem is that the merchandising invites a use its own labelling excludes.

What does Research Use Only mean? The product is supplied for laboratory investigation, not for administration to people or animals. It is not reviewed by FDA for safety or effectiveness, is not required to be sterile, and carries no clinical oversight. The vendor states this on its own product pages. Is it legal to buy? RUO reagents are lawfully sold for laboratory use. What is not lawful or safe is using them as unapproved drugs in humans, and the vendor's labelling excludes that use. Does 99% purity mean it is safe to inject? No. Purity and sterility are different tests. A vial can be highly pure and still contain bacteria or bacterial endotoxin, which causes fever and shock when injected. What are the actual risks? Non-sterile injection can cause abscess, cellulitis, sepsis and endocarditis. Reconstitution arithmetic errors cause overdoses. And if you become unwell, the clinician treating you does not know what you took. What about the GLP-1 products specifically? The approved molecules have strong trial evidence. That evidence belongs to pharmaceutical-grade products managed by a prescriber, and does not transfer to a research vial. Is BPC-157 proven? Essentially all evidence is in rodents. There are no adequate published human trials for the indications it is marketed for, FDA has categorised it as presenting significant safety risks for compounding, and it is prohibited in sport. Is ipamorelin safe? Growth hormone secretagogues are not appropriate for adults without diagnosed deficiency confirmed by endocrine testing. Risks include insulin resistance, fluid retention, joint pain and carpal tunnel syndrome. Will these fail a drug test? Several appear on the WADA Prohibited List. Strict liability applies in sport. What should I do instead if I want a GLP-1? See a clinician. Check manufacturer-direct self-pay pricing for the FDA-approved products, which has fallen substantially, and check your insurance. What if I already used one and feel unwell? Seek medical care immediately and tell them exactly what you took, the dose and the source. Fever, spreading redness at an injection site, severe pain or persistent vomiting are emergencies.